Main Characteristics of BMTs
| Patient No. . | HLA Incompatibility . | T-Cell Depletion Method . | Conditioning Regimen . | Engraftment3-150 . | GVHD . | Outcome . |
|---|---|---|---|---|---|---|
| 1 First BMT | A-B-DR | E-rosetting | VP16/CP/BU | 0% | ||
| Second BMT | A-B-DR | E-rosetting | ATG/CP/BU* | Full | I | Died 3 mo, disease progression |
| 2 | A-B-DR | E-rosetting | VP16/CP/BU | Full | 0 | Alive and well, 69 mo+ |
| 3 | B | C-1M+C | VP16/CP/BU | 0% | — | Died 10 mo, disease progression |
| 4 | A-B | E-rosetting | VP16/CP/BU | Full | Mild c-GVHD | Alive and well, 57 mo+ |
| 5 | A | E-rosetting | VP16/CP/BU | 0% | — | Died 3 mo, aplasia |
| 6 | A-B-DR | Anti-CD2/CD7+C | VP16/CP/BU | Full | 0 | Alive and well, 46 mo+ |
| 7 | A-B-DR | E-rosetting | VP16/CP/BU | 0% | — | Died 10 mo, disease progression |
| 8 First BMT | A-DR | E-rosetting | VP16/CP/BU | 0% | ||
| Second BMT | A-B-DR | E-rosetting | ATG/CP/BU | Full | 0 | Alive and well, 45 mo+ |
| 9 | A-B-DR | E-rosetting | VP16/CP/BU | Full | 0 | Alive and well, 31 mo+ |
| 10 | A-B-DR | E-rosetting | VP16/CP/BU | Full | 0 | Died 31 d, liver failure |
| 11 First BMT | A-B-DR | Anti-CD2/CD7+C | VP16/CP/BU | 0% | ||
| Second BMT | A-B-DR | Anti-CD2/CD7+C | ATG/CP/BU | 85% | 0 | Alive and well, 13 mo+ |
| 12 | A-B-DR | Anti-CD2/CD7+C | ATG/CP/BU | 56% | 0 | Alive and well, 14 mo+ |
| 13 | MUD | Anti-CD2/CD7+C | ATG/CP/BU | 80% | 0 | Alive and well, 8 mo+ |
| 14 | A-B-DR | E-rosetting | ATG/CP/BU | 90% | 0 | Alive and well, 9 mo+ |
| Patient No. . | HLA Incompatibility . | T-Cell Depletion Method . | Conditioning Regimen . | Engraftment3-150 . | GVHD . | Outcome . |
|---|---|---|---|---|---|---|
| 1 First BMT | A-B-DR | E-rosetting | VP16/CP/BU | 0% | ||
| Second BMT | A-B-DR | E-rosetting | ATG/CP/BU* | Full | I | Died 3 mo, disease progression |
| 2 | A-B-DR | E-rosetting | VP16/CP/BU | Full | 0 | Alive and well, 69 mo+ |
| 3 | B | C-1M+C | VP16/CP/BU | 0% | — | Died 10 mo, disease progression |
| 4 | A-B | E-rosetting | VP16/CP/BU | Full | Mild c-GVHD | Alive and well, 57 mo+ |
| 5 | A | E-rosetting | VP16/CP/BU | 0% | — | Died 3 mo, aplasia |
| 6 | A-B-DR | Anti-CD2/CD7+C | VP16/CP/BU | Full | 0 | Alive and well, 46 mo+ |
| 7 | A-B-DR | E-rosetting | VP16/CP/BU | 0% | — | Died 10 mo, disease progression |
| 8 First BMT | A-DR | E-rosetting | VP16/CP/BU | 0% | ||
| Second BMT | A-B-DR | E-rosetting | ATG/CP/BU | Full | 0 | Alive and well, 45 mo+ |
| 9 | A-B-DR | E-rosetting | VP16/CP/BU | Full | 0 | Alive and well, 31 mo+ |
| 10 | A-B-DR | E-rosetting | VP16/CP/BU | Full | 0 | Died 31 d, liver failure |
| 11 First BMT | A-B-DR | Anti-CD2/CD7+C | VP16/CP/BU | 0% | ||
| Second BMT | A-B-DR | Anti-CD2/CD7+C | ATG/CP/BU | 85% | 0 | Alive and well, 13 mo+ |
| 12 | A-B-DR | Anti-CD2/CD7+C | ATG/CP/BU | 56% | 0 | Alive and well, 14 mo+ |
| 13 | MUD | Anti-CD2/CD7+C | ATG/CP/BU | 80% | 0 | Alive and well, 8 mo+ |
| 14 | A-B-DR | E-rosetting | ATG/CP/BU | 90% | 0 | Alive and well, 9 mo+ |
Abbreviation: C, autologous complement.
Engraftment assessed on mononuclear cells by HLA typing or Y-specific probe.